6:04 AM ET
8-K
Investor Presentation
Neonc Technologies Holdings Investor Presentation
NeOnc Technologies Holdings, Inc. filed a formal corporate presentation for use in upcoming investor meetings, highlighting its clinical-stage CNS oncology platforms. The filing includes a clinical update for the NEO100 Phase 2a study, reporting an additional patient response that increased the objective response rate from 8.3% to 12.5%.